Evolus (EOLS) Short-term Investments (2019 - 2020)
Evolus' (EOLS) quarterly Short-term Investments came in at $5.0 million in Q4 2020, down 74.89% YoY from $19.9 million in Q1 2020, and down 80.0% on a QoQ basis from $25.0 million in Q3 2020.
Evolus (EOLS) Short-term Investments (2019 - 2020) Analysis & Trends
Evolus (EOLS) has 2 years of Short-term Investments data on file, last reported at $5.0 million in Q4 2020.
- Quarterly Short-term Investments fell 74.89% year-over-year to $5.0 million in Q4 2020, while the trailing twelve-month figure through Dec 2020 was $5.0 million (down 74.89% YoY) and the FY2020 annual result came in at $5.0 million, down 74.89% from the prior year.
- Short-term Investments retreated to $5.0 million in Q4 2020, from $25.0 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $79.3 million in Q1 2019 to a low of $5.0 million in Q4 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - |
| 10 | Evolus | 552.49 Mn | 507.32 Mn | 57.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2020 | 5.00 Mn |
| Sep 30, 2020 | 25.00 Mn |
| Jun 30, 2020 | 54.98 Mn |
| Mar 31, 2020 | 64.99 Mn |
| Dec 31, 2019 | 19.91 Mn |
| Sep 30, 2019 | 34.91 Mn |
| Jun 30, 2019 | 69.64 Mn |
| Mar 31, 2019 | 79.31 Mn |